Joseph Tremblay Claude
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Joseph Tremblay Claude has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Abigail M. Green
School of Medicine, Louisiana State University Health Sciences Center at Shreveport, Shreveport, USA
1 shared publication - Alan David Kaye
Department of Anesthesiology, Louisiana State University Health Shreveport, Shreveport, LA 71103, USA
1 shared publication - Charles P. Daniel
School of Medicine, Louisiana State University Health Sciences Center at Shreveport, Shreveport, USA
1 shared publication - Jada F. Cooley
School of Medicine, Louisiana State University Health Sciences Center at Shreveport, Shreveport, USA
1 shared publication - Kelly R. Sala
School of Medicine, Louisiana State University Health Sciences Center at New Orleans, New Orleans, USA
1 shared publication - Pooja Potharaju
Department of Anesthesiology, Louisiana State University Health Sciences Center Shreveport, Shreveport, USA
1 shared publication
Latest Publications
- 13 September 2024
- Published by Springer Nature in Advances in Therapy
- Vol. 41 (11) , 4299-4311
Efficacy and Safety of Alpha-2 Agonists in Autism Spectrum Disorder: A Systematic Review
Background This analysis is a systematic literature review assessing efficacy and adverse effects of three alpha-2 agonists for the symptomatic management of autism spectrum disorder (ASD). Methods The present investigation involved an extensive systematic search for eligible studies in PubMed, Embase, Cochrane Library, and Google Scholar. Nine studies, collectively incorporating 226 patients, were assessed. Results The results demonstrated promising indications for use of alpha-2 agonists in the symptomatic management of autism spectrum disorders, including improvement of hyperactivity, impulsivity, attention deficit symptoms, irritability, and stereotypies in many of the participants studied. Conclusion The present investigation encourages physicians to consider treatment outcomes of clonidine, guanfacine, and lofexidine to determine the most effective management of ASD-related symptoms and to minimize adverse effects. However, our review cannot provide definitive treatment protocols related to various study limitations.
- 13 September 2024
- Published by Springer Nature in Advances in Therapy
- Vol. 41 (11) , 4299-4311
Efficacy and Safety of Alpha-2 Agonists in Autism Spectrum Disorder: A Systematic Review
Background This analysis is a systematic literature review assessing efficacy and adverse effects of three alpha-2 agonists for the symptomatic management of autism spectrum disorder (ASD). Methods The present investigation involved an extensive systematic search for eligible studies in PubMed, Embase, Cochrane Library, and Google Scholar. Nine studies, collectively incorporating 226 patients, were assessed. Results The results demonstrated promising indications for use of alpha-2 agonists in the symptomatic management of autism spectrum disorders, including improvement of hyperactivity, impulsivity, attention deficit symptoms, irritability, and stereotypies in many of the participants studied. Conclusion The present investigation encourages physicians to consider treatment outcomes of clonidine, guanfacine, and lofexidine to determine the most effective management of ASD-related symptoms and to minimize adverse effects. However, our review cannot provide definitive treatment protocols related to various study limitations.